

Kyowa Hakko Kirin Co., Ltd.**Appendix to the Fiscal 2012 First Quarter Consolidated Financial Statements**

First quarter results for Fiscal 2012

(January 1, 2012 - March 31, 2012)

Index	Page
I. Consolidated Financial results	
1. Income	1
2. Results by segment	1
3. Non-operating income/expenses	2
4. Extraordinary income/losses	2
5. R&D expenses	3
6. Capital expenditure (tangible fixed assets)	3
7. Depreciation expenses	3
8. Exchange rates	3
II. Consolidated Subsidiaries and affiliates	4
III. Non-Consolidated Net sales by division	
1. Kyowa Hakko Kirin	5
2. ProStrakan	6
3. Kyowa Hakko Bio	6
R&D Pipeline	7

This document was made as a supplement to the Kessan Tanshin (financial report) for the first quarter of Fiscal 2012, the three-month period from January 1, 2012 to March 31, 2012. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

I. Consolidated Financial Results

There are no changes to the consolidated results forecasts for the fiscal year ending December 31, 2012 announced on January 31, 2012.

1. Trends in income

Millions of yen, rounded down

	FY 2011 results			FY 2012 results			FY 2012 forecasts	
	January 1 to March 31 (A)	January 1 to June 30	January 1 to December 31	January 1 to March 31 (B)	Change on January to March 2011		January 1 to June 30	January 1 to December 31
					Amount (B-A)	% (B/A)		
Net sales	114,862	186,367	343,722	87,111	(27,750)	76%	163,000	326,000
Gross Profit	56,644	100,234	197,555	55,016	(1,627)	97%	--	--
Selling, general and administrative expenses	34,734	70,297	150,940	36,976	2,242	106%	--	--
Operating income (prior to amortization of goodwill)	24,235	34,576	55,881	20,353	(3,882)	84%	27,127	57,255
Operating income	21,909	29,936	46,614	18,039	(3,870)	82%	22,500	48,000
Other income	1,280	1,316	2,233	1,660	380		--	--
Other expenses	937	1,040	2,093	3,125	2,187		--	--
Ordinary income	22,252	30,212	46,754	16,575	(5,677)	74%	19,500	42,500
Extraordinary income	8,265	8,421	7,332	--	(8,265)		--	--
Extraordinary expenses	3,214	5,363	7,903	324	(2,889)		--	--
Net income before income taxes	27,304	33,270	46,183	16,250	(11,053)	60%	19,500	41,000
Corporate, local and enterprise taxes	12,496	15,507	20,489	7,719	(4,776)		--	--
Income from minority interests	22	44	86	16	(5)		--	--
Net income	14,785	17,718	25,608	8,514	(6,271)	58%	8,500	20,000
Comprehensive income	15,426	16,745	18,693	15,003	(422)	97%	--	--
EPS before goodwill amortization (¥/share)	30.03	39.24	61.50	19.66			23.88	53.28

Notes : 1. Figures before goodwill amortization represent amounts prior to subtraction of the goodwill amortization* which occurred as a result of the reverse acquisition (exchange of Kirin Pharma Co. stock) implemented in April 2008.

* Goodwill amortization resulting from the acquisition of all outstanding shares of ProStrakan Group plc is not included in these adjusted figures.

2. On April 21, 2011, Kyowa Hakko Kirin acquired all outstanding shares of ProStrakan Group plc and as a result ProStrakan Group, and its ten subsidiaries newly were included in the scope of consolidation. In terms of accounting treatment, June 30, 2011 will be considered as the date that the acquisition was completed and therefore results from ProStrakan have not been included in the consolidated financial results for the first half of the current fiscal year. Financial results from ProStrakan as of July have been included in the financial results.

2. Trends in results by segment

(1) Results by operating segment

Millions of yen, rounded down

	FY 2011 results			FY 2012 results			FY 2012 forecasts	
	January 1 to March 31 (A)	January 1 to June 30	January 1 to December 31	January 1 to March 31 (B)	Change on January to March 2011		January 1 to June 30	January 1 to December 31
					Amount (B-A)	% (B/A)		
Net sales	114,862	186,367	343,722	87,111	(27,750)	76%	163,000	326,000
Pharmaceuticals	63,393	112,534	229,339	64,870	1,476	102%	120,000	242,000
Bio-Chemicals	19,686	40,360	77,563	20,589	902	105%	40,000	78,000
Chemicals	33,550	33,550	33,550	--	(33,550)	--	--	--
Other	2,651	5,306	10,659	2,557	(93)	96%	5,000	10,000
Total	119,281	191,752	351,113	88,016	(31,264)	74%	165,000	330,000
Eliminations	(4,419)	(5,384)	(7,390)	(905)	3,514	20%	(2,000)	(4,000)
Operating income	21,909	29,936	46,614	18,039	(3,870)	82%	22,500	48,000
<i>*Before goodwill amortization</i>	24,235	34,576	55,881	20,353	(3,882)	84%	27,127	57,255
Pharmaceuticals	18,419	25,145	41,314	16,638	(1,780)	90%	21,500	45,700
	20,576	29,459	49,942	18,795	(1,780)	91%	25,814	54,329
Bio-Chemicals	1,272	2,519	2,896	1,303	31	102%	800	2,000
	1,428	2,832	3,521	1,459	31	102%	1,113	2,626
Chemicals	2,135	2,135	2,135	--	(2,135)	--	--	--
	2,147	2,147	2,147	--	(2,147)	--	--	--
Other	82	148	360	94	11	114%	200	300
	82	148	360	94	11	114%	200	300
Total	21,909	29,948	46,706	18,036	(3,873)	82%	22,500	48,000
	24,235	34,588	55,973	20,349	(3,885)	84%	27,127	57,255
Eliminations	0	(12)	(92)	3	3	--	--	--

Notes: 1. Figures representing amount before goodwill amortization have been italicized

2. As regards the Chemicals Business, only results for chemical products from January 1 to March 31, 2011 have been consolidated due to the transfer of all shares of Kyowa Hakko Chemical on March 31, 2011

(2) Regional sales

Millions of yen, rounded down

	FY 2011 results						FY 2012 results	
	January 1 to March 31	Percentage of consolidated sales	January 1 to June 30	Percentage of consolidated sales	January 1 to December 31	Percentage of consolidated sales	January 1 to March 31	Percentage of consolidated sales
Japan	91,329	79.5%	148,987	79.9%	272,568	79.3%	68,921	79.1%
Overseas sales	23,532	20.5%	37,379	20.1%	71,154	20.7%	18,189	20.9%
America	6,837	6.0%	10,456	5.6%	20,071	5.8%	4,638	5.3%
Europe	6,060	5.3%	10,919	5.9%	25,169	7.3%	8,427	9.7%
Asia	10,499	9.1%	15,772	8.5%	25,426	7.4%	4,997	5.7%
Other regions	135	0.1%	231	0.1%	486	0.1%	127	0.1%
Total consolidated net sales	114,862	100.0%	186,367	100.0%	343,722	100.0%	87,111	100.0%

*Sales classified by region or country based on location of customer

3. Trends in non-operating income/expenses

Millions of yen, rounded down

	FY 2011 results			FY 2012 results
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31
Other income	1,280	1,316	2,233	1,660
Interest received	65	193	497	142
Dividends income	57	303	536	318
Foreign exchange gains	579	112	-	926
Equity in earnings of affiliates	166	141	199	-
Other	411	565	1,000	273
Other expenses	937	1,040	2,093	3,125
Interest expense	43	77	135	32
Foreign exchange loss	-	-	154	-
Loss from revaluation of derivatives	431	32	142	292
Equity in losses of affiliates	-	-	-	2,465
Loss from disposal of non-current assets	165	313	670	115
Other	296	617	990	218

4. Trends in extraordinary income / losses

Millions of yen, rounded down

	FY 2011 results			FY 2012 results
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31
Extraordinary income	8,265	8,421	7,332	-
Gain on sale of shares in affiliates	8,265	8,320	7,217	-
Allowance for doubtful accounts	-	100	115	-
Extraordinary losses	3,214	5,363	7,903	324
Loss from sale of investment securities	-	-	692	324
Loss from revaluation of investment securities	1,546	3,043	2,374	-
Advisory expenses	973	1,030	1,098	-
Asset impairment loss	-	200	769	-
Loss on disaster	118	302	650	-
Loss from sales of fixed assets	-	-	635	-
Extraordinary depreciation of fixed assets	-	-	477	-
Loss on adjustment for changes of accounting standard for asset retirement	447	447	447	-
Loss on business liquidation	-	-	419	-
Loss on liquidation of affiliates	-	209	209	-
Provision for point card certificates for prior periods	128	128	128	-

5. Trends in R&D expenses

Billions of yen, rounded down

	FY 2011 results			FY 2012 results	FY 2012 forecasts	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
R&D expenses (Consolidated)	10.8	22.2	47.9	11.0	23.9	46.1
R&D to net sales ratio (%)	9.4%	11.9%	14.0%	12.7%	14.7%	14.2%
Pharmaceuticals	9.8	20.4	44.5	10.3	22.3	42.9
(R&D to net sales ratio) (%)	15.6%	18.2%	19.4%	15.9%	18.6%	17.7%
Bio-Chemicals	0.7	1.5	3.2	0.7	1.5	3.1
Chemicals	0.2	0.2	0.2	-	-	-
Other	0.0	0.0	0.0	0.0	0.0	0.0

6. Trends in Capital Expenditure (Tangible fixed assets)

Billions of yen, rounded down

	FY 2011 results			FY 2012 results	FY 2012 forecasts	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
Capital expenditure (Consolidated)	3.1	5.9	14.3	4.1	11.5	23.9
Pharmaceuticals	1.4	2.8	6.5	2.1	5.4	11.7
Bio-Chemicals	1.3	2.7	7.4	1.9	6.0	12.2
Chemicals	0.3	0.3	0.3	-	-	-
Other	0.0	0.0	0.0	0.0	0.0	0.0

7. Trends in Depreciation Expenses

Billions of yen, rounded down

	FY 2011 results			FY 2012 results	FY 2012 forecasts	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
Depreciation expenses (Consolidated)	5.5	10.4	22.8	4.6	9.4	20.7
Pharmaceuticals	3.3	6.8	15.3	3.1	6.5	13.9
Bio-Chemicals	1.2	2.6	6.4	1.5	2.9	6.7
Chemicals	0.9	0.9	0.9	-	--	--
Other	0.0	0.0	0.0	0.0	0.0	0.0

8. Exchange rates

	FY 2011 results			FY 2012 results	FY 2012 forecasts	
	January 1 to March 31	January 1 to June 30	January 1 to December 31	January 1 to March 31	January 1 to June 30	January 1 to December 31
US Dollar (¥/US\$)	82	82	80	79	77	77
Euro (¥/Euro)	113	115	111	104	98	98
GBP (¥/GBP)	132	133	128	125	119	119

II. Consolidated Subsidiaries and Affiliates

(As of March 31, 2012)

Segment	Type	Region	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Japan	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
			Kyowa Medical Promotion Co., Ltd.	100.0%	Promotion and sales of pharmaceuticals
		The Americas	Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of subsidiaries (US)
			BioWa, Inc.	100.0%	Out-licensing of anti-body technology (US)
			Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products (US)
			Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
			Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
			Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)
			ProStrakan Inc.	100.0%	Sales of pharmaceuticals (US)
		Europe	ProStrakan Group plc	100.0%	Supervision and management of special companies (UK)
			Strakan International S.a r.l.	100.0%	Sales, licensing-in and licensing-out of pharmaceuticals (UK)
			Strakan Pharmaceuticals Limited	100.0%	Development of pharmaceuticals (UK)
			ProStrakan Limited	100.0%	Sales of pharmaceuticals (UK)
			ProStrakan Pharma S.A.S	100.0%	Sales of pharmaceuticals (France)
			ProStrakan Farmaceutica SLU	100.0%	Sales of pharmaceuticals (Spain)
			ProStrakan Pharma GmbH	100.0%	Sales of pharmaceuticals (Germany)
			ProStrakan Holdings B.V.	100.0%	Holding company for special companies (Netherlands)
			ProStrakan Pharma B.V.	100.0%	Sales of pharmaceuticals (Netherlands)
			ProStrakan S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
		Kyowa Hakko Kirin Italia S.r.l.	100.0%	Sales of pharmaceuticals (Italy)	
	Asia	Kirin Kunpeng (China) Bio- Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)	
		Jeil-Kirin Pharm. Inc.	90.0%	Sales of pharmaceuticals (Korea)	
		Kyowa Hakko Kirin (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)	
		Kyowa Hakko Kirin (Hong Kong) Co., Ltd.	100.0%	Sales of pharmaceuticals (Hong Kong)	
		Kyowa Hakko Kirin (Singapore) Pte. Ltd.	100.0%	Sales of pharmaceuticals (Singapore)	
	Affiliate accounted for by the equity method	Japan	FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.	50.0%	Development, manufacture and sale of biosimilar pharmaceuticals
		Europe	ProStrakan AB	50.0%	Sales of pharmaceuticals (Sweden)
Bio-Chemicals	Consolidated subsidiary	Japan	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
			Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
			Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
			Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
	The Americas	BioKyowa Inc.	100.0%	Manufacture and sale of amino acids (US)	
		Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)	
		Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US special companies (US)	
	Europe	Kyowa Hakko Europe GmbH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)	
		Kyowa Hakko Bio Italia S.r.l.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)	
	Asia	Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)	
Kyowa Hakko (H.K.) Co., Ltd.		100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong)		
Kyowa Hakko Bio Singapore Pte. Ltd.		100.0%	Sale and import/export of fine chemicals including amino acids (Singapore)		
Other	Consolidated subsidiary	Japan	Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, wholesale sales of food, etc.
	Affiliate accounted for by the equity method		Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol

Notes: Changes to the scope of consolidation (January 1, 2012 to March 31, 2012)
No applicable items

III. Net sales by division (Items and main products)

1. Kyowa Hakko Kirin

Billions of yen, rounded down

Pharmaceuticals division (non-consolidated)	Fiscal 2011 results			Fiscal 2012 results		FY2012 forecasts	
	January 1 to March 31 results (A)	January 1 to June 30 results	January 1 to December 31 results	January 1 to March 31 results (B)	Change on January 1 to March 31 (B/A)	January 1 to June 30	January 1 to December 31
Pharmaceuticals division total	59.8	104.6	206.0	57.8	97%	103.7	206.3
Indication / Product							
<i>ESA formulation</i> Nesp	11.9	25.4	56.4	13.8	116%	25.5	50.5
<i>ESA formulation</i> Espo	1.3	2.7	5.3	0.9	72%	2.0	4.0
Nesp/Espo	(13.3)	(28.2)	(61.8)	(14.8)	(111%)	(27.5)	(54.5)
<i>Secondary hyperparathyroidism</i> Regpara	2.5	5.3	11.5	2.8	112%	6.3	13.1
<i>Antiallergenic</i> Allelock	13.7	18.1	29.1	9.9	72%	16.9	29.7
<i>Antiallergenic</i> Celtect	0.7	1.3	2.5	0.5	69%	0.9	1.7
<i>Antiallergic eyedrops</i> Patanol	7.3	8.6	11.4	5.4	74%	8.1	11.3
<i>G-CSF</i> Gran	3.3	6.7	14.8	2.9	89%	6.3	13.3
<i>Cancer pain</i> Fentos	0.4	1.2	3.1	0.8	186%	2.3	4.9
<i>Anticancer</i> 5-FU	0.7	1.5	3.1	0.6	91%	1.3	2.7
<i>Anticancer</i> Navelbine	0.4	0.8	1.7	0.3	72%	0.7	1.4
<i>Cardiovascular</i> Coniel	4.6	9.6	19.7	4.2	90%	8.7	17.3
<i>Cardiovascular (Hypertension)</i> Coversyl	0.9	1.9	3.9	0.8	86%	1.7	3.4
<i>Cardiovascular</i> Inovan / Pre Dopa	0.7	1.3	2.8	0.6	85%	1.1	2.3
<i>Antiepileptic</i> Depakene	2.6	5.3	11.2	2.4	94%	5.3	10.7
<i>Parkinson's disease</i> Permax	0.5	1.1	2.1	0.3	74%	1.0	2.0
<i>Gastrointestinal</i> Nauzelin	1.2	2.3	4.8	1.1	88%	2.4	4.9
<i>Inflammatory bowel disease</i> Asacol	0.5	1.1	2.8	0.8	152%	1.9	4.1
Exports and Technology Out-Licensing	7.6	11.4	22.3	11.3	148%	16.1	33.3

2. ProStrakan

Millions of GBP, rounded down

Pharmaceuticals division	FY 2011 results			FY 2012 results		FY 2012 forecasts	
	January 1 to March 31 (A)	January 1 to June 30	January 1 to December 31	January 1 to March 31 (B)	Change on January to March 2011 (B/A)	January 1 to June 30	January 1 to December 31
Net sales	23	48	105	29	126%	60	142
Chemotherapy-induced nausea and vomiting drug Sancuso	2	4	9	2	138%	7	16
Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Abstral	5	12	27	7	128%	18	38
Replacement therapy with testosterone for male hypogonadism Tostran	0	2	5	1	167%	2	4
Prevention and treatment of post-operative nausea and vomiting (PONV). Xomolix	2	4	8	2	98%	4	9
Relief of pain associated with chronic anal fissure. Rectogesic	2	4	9	2	99%	5	10
Osteoporosis drug Adcal-D3	5	11	24	5	107%	11	24
Others	4	8	20	6	153%	10	38
Gross profit	15	29	65	19	129%	40	94
Selling, general and administrative expenses	18	40	75	18	100%	40	80
Operating income (prior to consolidated adjustment)	(3)	(11)	(9)	0	-	0	14
Consolidated adjustment				(9)		(16)	(32)
Operating income (after consolidated adjustment)				(8)		(16)	(17)

Notes: 1. ProStrakan has been included in the consolidated results as of July 2011

2. FY 2011 results based on ProStrakan local accounting standards (IFRS) while FY 2012 forecasts are shown on a consolidated basis.

Consolidated adjustment amounts are for noncurrent intangible assets (sales rights, etc.) and the amortization of the goodwill resulting from the occurrence of goodwill following the acquisition of ProStrakan Group plc. Operating income (after consolidated adjustment) are Kyowa Hakkō Kirin figures after consolidation.

3. Sales ratio by region as follows:

*Sales ratio by region
(January 1 to March 31, 2012)

UK	Europe (excluding UK)	USA	Other	Total
32.9%	44.2%	21.5%	1.4%	100.0%

3. Kyowa Hakkō Bio

Billions of yen, rounded down

Bio-Chemicals division (non-consolidated)	FY 2011 results			FY 2012 results		FY 2012 forecasts	
	January 1 to March 31 (A)	January 1 to June 30	January 1 to December 31	January 1 to March 31 (B)	Change on January to March 2011 (B/A)	January 1 to June 30	January 1 to December 31
Bio-Chemical division total	12.3	25.9	49.6	12.9	105%	26.2	52.3
Pharmaceuticals / Industrial raw materials							
Amino acids	4.5	10.1	19.1	5.0	109%	10.0	20.1
Nucleic acids and vitamins	1.2	2.7	5.2	1.3	107%	2.5	5.1
Other	1.7	3.8	7.2	1.7	100%	3.3	6.8
Health care products	2.1	4.7	9.3	2.2	105%	5.2	10.5

R&D Pipeline

Filed • Approved



antibody



protein



small molecule

As of Apr 18th 2012

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	Approved in Japan Mar/2012	In-House	POTELLIGENT®
	Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Filed in Asia	Kirin-Amgen	Asia: Korea and Vietnam
	Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in Asia	Licensed from NPS	Asia: Philippine, Malaysia, Thailand and China
	KW-6500 Apomorphine Hydrochloride Injection	Dopamine Receptor Agonist	Parkinson's Disease	Approved in Japan Mar/2012	Licensed from Britannia Pharmaceu- ticals Limited	
	KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Filed in USA Filed in Japan	In-House	
	AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	Filed in Taiwan Approved in Singapore Feb/2012	Kirin-Amgen	
	Sancuso Granisetron Patch	5HT ₃ Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Filed in Asia	Solasia Pharma (ProStrakan)	Asia: Taiwan and Singapore

Phase II, Phase III

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	KW-2246 Fentanyl citrate Sublingual Tablet	μ-Opioid Receptor Agonist	Cancer Pain	Phase III in Japan	Licensed from Orexo	Launched by ProStrakan for Abstral.
	KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Chemotherapy induced Febrile Neutropenia	Phase III in Japan	Kirin-Amgen	
	ARQ 197 Tivantinib Oral	c-Met Inhibitor	Lung Cancer Gastric Cancer	Phase III in Japan, Korea and Taiwan Phase II in Japan and Korea	Licensed from ArQule	
	KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	☆ Pediatric Renal Anemia Renal Anemia (on Dialysis) ☆ Myelodysplastic Syndrome related Anemia	Phase III in Japan Phase II in China Phase III in India Phase II in Japan and Korea	Kirin-Amgen	Launched in Japan for Anemia of CKD Patients
	KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	☆ HyperCalcemia with Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism	Phase III in Japan	Licensed from NPS	Launched in Japan for Secondary Hyperparathyroidism
	KW-6485 Topiramate Oral	Antiepileptic Drug	☆ Pediatric Epilepsy	Phase III in Japan	Licensed from Janssen Pharmaceutical K.K.	Launched in Japan for Use as an Antiepileptic Drug
	KW-3357 Antithrombin Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase III in Japan Phase I in Europe	In-House	
	KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma, Add-on Therapy (for Untreated Patients) Peripheral T/NK-cell Lymphoma Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma	Phase II in Japan Phase II in Japan Phase I / II in USA	In-House	POTELLIGENT®

Updated since Jan 24th, 2012 (Area, Stage, Filed, Approved, Launched etc.)






☆ New indication

R&D Pipeline (continued)










Phase II, Phase III

 antibody
  protein
  small molecule

As of Apr 18th 2012

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	KW-2478 Injection	HSP90 inhibitor	Multiple Myeloma	Phase I / II in UK/US/PH	In-House	
	ASKP 1240 Injection	Anti-CD40 Fully Human Antibody	Organ Transplant Rejection	Phase I in Japan Phase II in USA	In-House	Jointly Developed with Astellas KM mouse™
	RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in patients with type 2 diabetes	Phase II in Japan	Licensed from Reata	
	KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Phase II in Japan and Korea	In-House	Being Developed by MedImmune as MEDI- 563 Worldwide except in Japan and other Asian Countries POTELLIGENT®
	Z-206 Mesalazine Oral	pH Dependent Controlled Release Tablet	☆ Crohn's Disease	Phase II in Japan	Licensed from Zeria Pharma.	Jointly Developed with Zeria Pharma Launched in Japan for Ulcerative Colitis.

Phase I

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	KW-2450 Oral	IGF-1 Receptor Signal Inhibitor	Cancer	Phase I / II in USA	In-House	
	KRN330 Injection	Anti-A33 Fully Human Antibody	Cancer	Phase I / II a in USA	In-House	KM mouse™
	B I W-8962 Injection	Anti-GM2 Humanized Antibody	Cancer	Phase I / II a in USA	In-House	POTELLIGENT®
	KRN951 Tivozanib Oral	VEGF Receptor Inhibitor	Cancer	Phase I in Japan	In-House	
	KHK2866 Injection	Anti-HB-EGF Humanized Antibody	Cancer	Phase I in USA	In-House	POTELLIGENT®
	LY2523355 Litronesib Injection	M phase Kinesin Eg5 Inhibitor	Cancer	Phase I in Japan	In-House	
	CEP-37250/KHK 2804 Injection	Anti-Tumor Specific Glycoprotein Humanized Antibody	Cancer	Phase I in USA	Cephalon	Jointly Developed with Cephalon POTELLIGENT®
	KHK2898 Injection	Anti-CD98 Fully Human Antibody	Cancer	Phase I in Singapore	In-House	POTELLIGENT® KM mouse™
	KHK4827 Injection	Anti-IL-17 Receptor Fully Human Antibody	Psoriasis	Phase I in Japan	Kirin-Amgen	
	KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	☆ Asthma	Phase I in Japan	In-House	POTELLIGENT®
	KHK6188 Oral	Cannabinoid CB2 Receptor Agonist	Neuropathic Pain	Phase I in Japan	In-House	
	KRN23 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)	Phase I / II in USA and Canada	In-House	KM mouse™

Updated since Jan 24th, 2012 (Area, Stage, Filed, Approved, Launched etc.)

☆ New indication






R&D Pipeline (continued)

Updated since Jan 24th, 2012 (Area, Stage, Filed, Approved, Launched etc.)


 antibody
  protein
  small molecule

Filed • Approved


As of Apr 18th 2012

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	<u>Approved in Japan</u> Mar/2012	In-House	POTELLIGENT®
	KW-6500 Apomorphine Hydrochloride Injection	Dopamine Receptor Agonist	Parkinson's Disease	<u>Approved in Japan</u> Mar/2012	Licensed from Britannia Pharmaceuticals Limited	
	AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Idiopathic (Immune) Thrombocytopenic Purpura	<u>Approved in Singapore</u> Feb/2012	Kirin-Amgen	
	KW-6002 Istradefylline Oral	Adenosine A2a Receptor Antagonist	Parkinson's Disease	<u>Filed in Japan</u>	In-House	
	Sancuso Granisetron Patch	5HT ₃ Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Filed in Asia	Solasia Pharma (ProStrakan)	Asia: Taiwan and Singapore

Phase II, Phase III

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in patients with type 2 diabetes	Phase II <u>in Japan</u>	Licensed from Reata	

Phase I

	Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
	KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	☆ Asthma	Phase I <u>in Japan</u>	In-House	POTELLIGENT®